WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that Chief Executive Officer Wes Kaupinen will present at two major investor conferences in September.
The company is scheduled to host a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 p.m. ET. Palvella will also deliver a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 10:30 a.m. ET.
Live webcasts of both presentations will be available through Palvella’s website, with replays accessible for approximately 90 days.
Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases that currently lack FDA-approved treatments. Its lead candidate, QTORIN™ rapamycin, is under evaluation in a Phase 3 SELVA trial for microcystic lymphatic malformations and a Phase 2 TOIVA trial for cutaneous venous malformations. The therapy remains investigational and has not yet received regulatory approval.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.